logo
  

Stock Alert: UniQure Down 20%

Shares of UniQure (QURE) tanked nearly 20% in morning trade on Thursday. The company a day ago announced that CSL Behring (CSL) would acquire exclusive commercialization rights to its gene-therapy program.

CSL Behring will acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061, for the treatment of hemophilia B from uniQure.

The AMT-061 program, currently in Phase 3 clinical trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with hemophilia B.

UniQure will receive a $450 million upfront payment.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT